Tilray: Schedule III Tailwind Meets a Discounted Valuation — A Tactical Long
Tilray is trading like a distressed cannabis play while its distribution and beverage businesses produce real revenue growth and federal rescheduling creates a structural tax tailwind for medical products. With market cap under $600M, EV/Sales ~0.54 and price-to-book ~0.35, this is a trade for disciplined longs who believe Schedule III will unlock …